Humacyte, a privately held company, is primarily focused on developing investigational products for vascular disease and for replacement of anatomical conduits. The company uses its innovative and proprietary platform technology to engineer human, extracellular matrix-based investigational tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. Incorporated in 2004, Humacyte has licensed technology from MIT, Yale, and Duke University. Since then, Humacyte has made considerable progress in the development, pre-clinical, and clinical testing of our human acellular vessels (HAV).Read More »
Pre-clinical and clinical data suggests Humacyte human acellular vessels (HAV) may have the potential to extend patency with the possibility of some reduction in inflammation and some reduction in clotting.
Humacyte human acellular vessels may have the potential to be less immunogenic with the possibility of some reduction in foreign body response.
Humacyte human acellular vessels may have the potential to lower healthcare costs with reduced surgical interventions and more positive, long term, clinical outcomes.
RESEARCH TRIANGLE PARK, N.C., — November 9, 2015 – Jeffrey H. Lawson, M.D., Ph.D., Chief Medical Officer of Humacyte, an innovator in biotechnology and vascular regenerative medicine, will present three sessions at the leading vascular specialist conference, the VEITHsymposium, November…Read More »
RESEARCH TRIANGLE PARK, N.C. — Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Company founder, Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies, will address the American Heart Association (AHA) Scientific Sessions….Read More »